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β-nitrostyrene compounds, such as 3,4-methylenedioxy-β-nitrostyrene (MNS), inhibit growth and induce apoptosis in tumor
cells, but no reports have investigated their role in osteosarcoma. In this study, human osteosarcoma cell families with cell
lines of varying tumorigenic and metastatic potential were utilized. Scrape motility assays, colony formation assays, and colony
survival assays were performed with osteosarcoma cell lines, both in the presence and absence of MNS. Eﬀects of MNS on human
osteoblasts and airway epithelial cells were assessed in monolayer cultures. MNS decreased metastatic cell line motility by 72–76%
and colony formation by 95–100%. MNS consistently disrupted preformed colonies in a time-dependent and dose-dependent
manner. MNS had similar eﬀects on human osteoblasts but little eﬀect on airway epithelial cells. An inactive analog of MNS had
no detectable eﬀects, demonstrating speciﬁcity. MNS decreases motility and colony formation of osteosarcoma cells and disrupts
preformed cell colonies, while producing little eﬀect on pulmonary epithelial cells.
1.Introduction
Osteosarcoma, the most common malignant bone tumor in
children and adolescents, aﬀects nearly 560 new individuals
each year in the United States [1]. Among other prognostic
indicators, metastases on presentation and poor response
to preoperative chemotherapy are markers for a dismal
outcome [2–4]. Approximately 20% of new cases present
with clinically detectable metastases; however, current pro-
tocols provide treatment addressing presumed presence of
pulmonary micrometastases [2, 5]. The pulmonary system
is the most common site of distant metastasis with distant
bony sites second [4]. The addition of liposomal muramyl
tripeptide phosphatidylethanolamine to chemotherapeutic
regimens and surgical resection has resulted in ﬁve-year
survival rates of 78% and 53% for patients without and
with metastases, respectively [6, 7]. The continued high
mortality rates for children and adolescents with metastatic
osteosarcoma outlines the need for further research into the
development of novel therapeutics.
Beta-nitrostyrenes have recently been found to inhibit
tumor cell growth and induce apoptosis through dis-
ruption of tubulin polymerization, inhibition of protein
phosphatases, and inhibition of telomerase activity [8–10].
3,4-methylenedioxy-β-nitrostyrene (MNS), a synthesized β-
nitrostyrene, is reported to inhibit Syk and Src tyrosine
kinase activity [11, 12]. Tyrosine kinases participate in
the regulation of cell proliferation, migration, motility,
colony formation, invasiveness, and apoptosis [13, 14].
Thus, tyrosine kinases participate in important processes
which are critical for the survival, growth, and metastatic
potentialoftumorcells.Inhibitorymoleculesofreceptorand2 Sarcoma
Table 1: Small molecule inhibitors and inactive MNS analogue.
Inhibitor Catalog number Concentration used Reference number
MNS (Syk III) 574713a 20μM( 5 xI C 50)[ 11, 12]
Src Inhibitor (SU6656) 572635a 0.5μM( 2 xI C 50)[ 30]
Syk I 574711a 1.5μM( 5 xI C 50)[ 31]
Syk II 574712a 2.3μM( 5 xI C 50)[ 32]
Syk IV (Bay 61-3606) 574714a 0.2μM( 5 xI C 50)[ 33]
Inactive MNS Analogue (MCA) 146242b 10μM( I C 50 > 100μM) [11]
a:C a l b i o c h e m ;b:S i g m a - A l d r i c h .
non-receptor tyrosine kinases targeting epidermal growth
factor receptor, nerve growth factor receptor, ErbB-2/neu,
insulin-like growth factor-1 receptor, hepatocyte growth
factor receptor (met/HGF-R), platelet-derived growth factor
receptors, and Janus family protein kinases have been
investigated as potential chemotherapeutic agents for the
treatment of osteosarcoma, for their roles in reducing tumor
cell growth, motility, invasiveness, and colony formation
[14, 15]. Syk, a non-receptor tyrosine kinase, is involved in
signaling pathways and cell-cycle control with the majority
of research to this date focused on the role of aberrant Syk
expression and/or signaling in hematopoietic lineage cells,
hematopoietic cancer, lung carcinoma, and gastric tumors
[16]. Recent evidence demonstrates the presence of activated
Syk in human osteosarcoma cells [17, 18]. Syk-dependent
signalingpathwaystargetthephosphorylationandactivation
of phosphatidylinositol 3-kinase and phospholipase C-γ2
[19, 20]. Additionally, Syk signaling pathways interact with
members of the non-receptor tyrosine kinase Src family
[21, 22]. c-Src expression results in the activation of critical
participants for cell growth, angiogenesis, migration and
invasion in several types of sarcomas, including osteosar-
coma [23–25].
First, we asked whether MNS, a synthesized β-nitrosty-
rene derivative, alters the motility, colony formation, and
colony survival of osteosarcoma cell lines. Second, we asked
whether MNS aﬀects normal, human osteoblasts and small
airway epithelial cells since metastases primarily involve lung
parenchyma and nasal administration of chemotherapeutics
is being developed for osteosarcoma [26].
2.MaterialsandMethods
Two families of genetically-related osteosarcoma cell lines
wereused,witheachparentalcelllineharvestedfromhuman
osteosarcoma tissue. The TE85 family was obtained from
the American Type Culture Collection (Manassas, VA, USA)
and included a parental cell line (TE85: little tumorigenic or
metastatic potential) and two derivative cell lines (MNNG:
tumorigenicbutweaklymetastatic;143B:highlytumorigenic
and metastatic) [27]. The SAOS-2 family was obtained from
Dr. E. Kleinerman, MD (Anderson Cancer Center, Houston,
TX, USA) and included a parental cell line (SAOS-2: little
tumorigenic or metastatic potential) and a derivative cell
line (LM7: highly tumorigenic and metastatic) [28, 29].
Unless otherwise speciﬁed, all cell cultures were maintained
according to a previously described method [14]. Cells
were harvested during the mid-log phase of growth for all
experiments.
Theeﬀectsof smallmolecule inhibitors wereusedin tests
of motility, nonadherent colony formation, or nonadherent
colony survival. Small-molecule inhibitors and inactive
analogues were obtained from Calbiochem (San Diego, CA,
USA) and Sigma-Aldrich (St. Louis, MO, USA) and the
concentrations of small molecule inhibitors used were based
on publications demonstrating the eﬀective concentrations
in intact cell assays (Table 1). Inhibitors were dissolved in
dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO, USA),
with the exception of Syk IV (H2O), and aliquots were stored
at −20◦C.
Scrape motility assays were performed similarly to a
previously described method [14, 34, 35]. Brieﬂy, cells (1.0×
105 per 9.6cm2 well) were cultured to form a conﬂuent
monolayerbeforescrapesweremadeusinga1mLpipettetip.
Thechamberswereincubatedinthepresenceofinhibitorsor
vehicle controls. Each scrape was photographed immediately
and at the indicated time points using the 10x objective
on a Leica DM IRB inverted, phase contrast microscope
(LeicaMicrosystems,Deerﬁeld,IL,USA).Scrapewidthswere
measured with ImageJ (NIH). Motility was calculated by
subtracting the scrape width at the indicated time points
from the initial scrape width and dividing by two.
Colony formation assays were performed similarly to a
previously described method [14, 27]. Brieﬂy, 8.0 × 103 cells
weresuspendedinrattailtypeIcollagengel(BDBiosciences,
Bedford, MA, USA) overlying a lower layer of collagen
gel in a 2cm2 culture well. Gels were then covered with
media plus inhibitors, inactive analogue, or vehicle controls.
Media, inhibitors, and vehicle controls were changed every
48 hours. Colonies (≥5 intactcells)werecountedafter3 days
(TE85, MNNG, 143B) or 6 days (SAOS-2, LM7) using phase
contrast microscopy.
Non-adherent colony survival assays were performed
by a modiﬁcation of the colony formation assays. Brieﬂy,
colonies were allowed to form as described in the previous
paragraph for 3 (TE85, MNNG, 143B) or 6 (SAOS-2, LM7)
days and then gels were incubated with 1mL of media
containing 10% FBS plus suﬃcient levels of the small
molecule inhibitors, inactive analogue, or vehicle controls
(DMSO or H2O depending on the inhibitor) to obtain
the indicated concentrations. Media, inhibitors, and vehicle
controls continued to be changed every 48 hours. Colonies
(≥5intactcells)wereanalyzedaftertheindicatedtimesusing
phase contrast microscopy.Sarcoma 3
Membrane integrity was assessed by DAPI staining of
non-permeabilized cells. DAPI was added to the media
overlying collagen gels 8 hours after initial treatment with
MNS, inactive analogue, or vehicle control. Phase contrast
and ﬂuorescent microscopy images were obtained at the 24
hour time point.
The eﬀects of MNS on normal, human osteoblasts
(Cambrex, East Rutherford, NJ) and normal, human, small
airway epithelial cells (ATCC, Washington, D.C., USA)
were assessed in monolayer cultures. Brieﬂy, cells (1.0 ×
105 per 9.6cm2 well) were cultured to form a conﬂuent
monolayer. Small airway epithelial cells were cultured in
Airway epithelial cell basal medium (ATCC, Washington,
D.C., USA) supplemented with bronchial epithelial cell
growth kit (ATCC, Washington, D.C., USA). Cells were
incubated in the presence of inhibitor, inactive analogue,
or vehicle control. At the indicated time points, media was
changed to remove non-adherent cells and phase contrast
microscopy was used to analyze the cells.
Expression of src and syk mRNAs was determined by real
time RT-PCR as described previously [36]. Total RNA was
isolated using the ToTALLY RNA kit (Ambion, Austin, TX,
USA).RNA(0.2μg)wasreversetranscribedintocDNAusing
SuperScript II reverse transcriptase (Invitroge, Carlsbad, CA,
USA). Quantitative RT-PCR was performed with SYBRgreen
PCR Master Mix (BioRad, Hercules, CA, USA) and the 7500
real-time PCR systems and Sequence Detection Software
(Applied Biosystems, Foster City, Ca, USA). Gene expression
was analyzed using a standard curve as previously described
[36].
The eﬀects of MNS on activity of tyrosine kinases was
determined biochemically using recombinant forms of the
kinases (KinaseProﬁler Service, Millipore, Billerica, MA) as
described [37].
Statistical analysis was determined by ANOVA with
the Bonferroni post-hoc tests performed for all analyses
(SigmaStat, San Jose, CA, USA). All ﬁgures illustrate mean
± standard error of the mean.
3. Results
MNS slowed motility of all osteosarcoma cell lines in a dose-
dependent manner (Figure 1). The motility of the metastatic
143B cell line was decreased by 52% at 5μMo fM N Sa n d
76% at 10μM of MNS, while the motility of the tumorigenic
but non-metastatic MNNG cells was decreased by 22% at
5μM of MNS and 64% at 10μMo fM N S( Figure 1). MNS
had less of an eﬀect on the non-tumorigenic, parental TE85
cells reducing the motility by 13% at 5μMo fM N Sa n d3 8 %
at 10μMo fM N S( Figure 1). MNS reduced motility of the
non-tumorigenic, parental SAOS-2 and metastatic LM7 cell
lines by 40% and 31% at 5μMo fM N S ,r e s p e c t i v e l y ,a n db y
81% and 72% at 10μMo fM N S ,r e s p e c t i v e l y( Figure 1). The
inactive analogue of MNS did not alter the motility of the
osteosarcoma cell lines (Figure 1).
MNS reduced the non-adherent colony formation of
all osteosarcoma cell lines in a dose-dependent manner
(Figure 2). Colony formation in collagen gels was reduced
by 95–100% for all osteosarcoma cells lines in the presence
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Figure 1: MNS reduced motility in a dose-dependent manner
in the osteosarcoma cell lines. Motility was measured 4 hours
after scraping in the presence of the indicated concentrations of
MNS, 10μM of the inactive analogue, or 1% DMSO as a vehicle
control. Data are represented as means ± SE of three independent
experiments, each with four scrapes per group. Average migration
distanceforvehiclecontrolgroupswere58μmforTE85cells,41μm
for MNNG cells, 60μm for 143B cells, 26μm for SAOS-2 cells,
and 18μm for LM7 cells. Asterisks denote diﬀerences in motility
compared with the vehicle control group (10μMM N S :T E 8 5( P =
0.020),MNNG(P = 0.009),143B(P<0.001),SAOS-2(P<0.001),
LM7 (P = 0.001); 5μM MNS: 143B (P<0.001), SAOS-2 (P =
0.002)).
of 5.0μMM N S( Figure 2). The inactive analogue of MNS
did not alter colony formation by the osteosarcoma cell lines
(Figure 2).
MNSrapidlyanddose-dependentlydisruptedpreformed
colonies of 143B cells (Figure 3). No obvious eﬀects were
seen at 1μMo fM N S( Figure 3). With MNS concentrations
of 2.5μMa n d5 μM, increasing cellular fragmentation is
demonstrated and membrane projections are still visible
(Figure 3). At 10μM of MNS, cells lose their membrane pro-
jections, become more “rounded” morphologically, and lose
their cohesiveness as a colony (Figure 3). These detrimental
changes occurred within 4 hours of exposure (Figure 3).
Cell death was conﬁrmed based on loss of membrane
integrity, which occurs within 24 hours of exposure as
assessed by DAPI staining (Figure 4).
TE85, MNNG, SAOS-2, and LM7 osteosarcoma cell lines
were also disrupted in a similar dose-dependent manner
(only 10μM dose shown, Figure 5). The inactive analogue
of MNS had no detectable eﬀect on the osteosarcoma cells
(Figures 3, 4, 5).
Monolayer cultures were used to compare the eﬀects
o fM N So nt h eo s t e o s a r c o m ac e l l sw i t hi t se ﬀects on
primary cultures of normal, human osteoblasts and normal,
human small airway epithelial cells since neither of the
normal cell types form non-adherent colonies. Moreover,
mature osteoblasts and epithelial cells are both organized in
monolayers in normal, physiologic conditions. In monolayer4 Sarcoma
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Figure 2: MNS reduced colony formation in a dose-dependent
manner in the osteosarcoma cell lines. Colonies were counted 24
hours after plating in collagen gel in the presence of MNS, an
inactive analogue, or 1% DMSO as a vehicle control. Data are
represented as means ± SE of three independent experiments, each
with three wells per group. Average colony formation per well for
vehicle control groups were 141 for TE85 cells, 133 for MNNG
cells, 187 for 143B cells, 152 for SAOS-2 cells, and 115 for LM7
cells. Asterisks denote P<0.05 compared with the vehicle control
group. Double asterisks indicate all cell lines were P<0.05 at
2.5, 5, and 10μMM N S( 1 0μM MNS: TE85 (P<0.001), MNNG
(P<0.001), 143B (P<0.001), SAOS-2 (P<0.001), LM7 (P<
0.001); 5μM MNS: TE85 (P<0.001), MNNG (P<0.001), 143B
(P<0.001), SAOS-2 (P<0.001), LM7 (P<0.001); 2.5μM MNS:
TE85 (P<0.001), MNNG (P<0.001), 143B (P<0.001), SAOS-
2( P<0.001), LM7 (P<0.001); 1μM MNS: TE85 (P = 0.002),
SAOS-2 (P = 0.040), LM7 (P = 0.0340).
culture, 10μM MNS had no detectable eﬀect on any of the
cell types but 100μM MNS substantially disrupted both the
143B osteosarcoma cells and the normal, human osteoblasts
(Figure 6). On the contrary, 100μM MNS only induced a
minimal morphological change in the small airway epithelial
cells, but these pulmonary cells remained alive and viable
(Figure 6). Thus, the eﬀects seen here by MNS preferen-
tially disrupting metastatic osteosarcoma cells while sparing
pulmonary cells could be utilized in chemotherapeutic
drug development. Osteosarcoma patients with pulmonary
metastases may beneﬁt from an intranasally-based MNS
compound and experience less drug-related morbidity.
MNS has been reported to inhibit the tyrosine kinase
activity of src and syk [11, 12]. Expression of mRNAs
encoding these kinases was therefore measured in the
osteosarcomacelllinesbyreal-timeRT-PCR.Sykwasreliably
detected only in the TE85 and LM7 cell lines (Figure 7(a)),
while src was expressed at low, but reproducible levels in all
ﬁve cell lines (Figure 7(b)).
The eﬀect of MNS on the osteosarcoma cell lines was
compared with a src inhibitor and three additional syk
inhibitors [12, 31, 32]. Although the eﬀect of MNS was
conﬁrmed in these experiments (Figures 8(a)–8(c)), neither
the src or other syk inhibitors, alone or in combination,
mimicked the eﬀects of MNS on motility (Figure 8(a))o r
colony formation (Figures 8(b) and 8(c)). These results
suggest that the eﬀects of MNS are due either to the
combined inhibition of Src or Syk and an additional tyrosine
kinase(s) or to inhibition of tyrosine kinases other than Src
and Syk.
To determine what other tyrosine kinases might be
inhibited by MNS, its eﬀects on the activity of recombinant
kinases was determined. As expected [11, 12], MNS did not
eﬀect activity of Fak or JAK2 (Figure 9(a)). Figure 9(a) also
shows that MNS had no eﬀect on activity of the twelve
tyrosine kinases that we have found to be activated in the
143B and LM7 cells [38]. In contrast to the results by Wang
et al. [11, 12], MNS also did not inhibit activity of Src or Syk,
even when the MNS concentration was increased to 100μM
and/or the ATP concentration in the reaction was reduced to
10μM (Figures 9(a) and 9(b)).
4. Discussion
MNS is an attractive lead compound for the development of
a novel chemotherapeutic option for patients suﬀering from
osteosarcoma. MNS signiﬁcantly reduced osteosarcoma cell
motility and colony formation, but the eﬀects were more
substantial in colony formation assays. MNS consistently
disrupted preformed colonies in a time-dependent and
dose-dependent manner while having little eﬀect on airway
epithelial cells. In contrast, the inactive analogue of MNS
did not cause deleterious eﬀects for either osteosarcoma or
airway epithelial cells, and thus, demonstrated speciﬁcity of
the MNS eﬀects.
Other authors have reported that MNS inhibits the
tyrosine kinase activity of syk, and at higher concentrations,
will inhibit the kinase activity of src [11, 12]. However, the
concentration of MNS used in this study was below the
reported IC50 (29.3μM) for inhibition of src and therefore
likely does not account for the observed results [12].
Additionally, the use of alternative syk inhibitors did not
produce reduction in motility, colony formation, or colony
survival as seen in the presence of MNS. The combination
of the src inhibitor with either the Syk I, Syk II, or Syk
IV inhibitors also did not produce results similar to MNS
alone. Furthermore, biochemical assays showed that MNS
didnotinhibittheactivityofsyk,src,orthe12othertyrosine
kinases that have been shown to be activated in these cell
lines [38]. Our results demonstrate the eﬀect of MNS in the
tumorigenic and metastatic assays is not due to syk or src
inhibition, but rather to another mechanism(s) which is yet
to be identiﬁed. The uncertainty as to the molecular target
of MNS does not preclude its usefulness as a lead compound
for development of novel chemotherapeutics.
Potential mechanisms for explanation of the observed
results are based on the core structure of MNS. MNS is
derived from a β-nitrostyrene moiety with an aromatic ring
and nitrovinyl side chain, both of which are critical to the
drug’s biological activity [39]. Compounds with a similar
structurehavebeenimplicatedingrowthinhibitionandpro-
apoptoticfunctions[8–10,39–41].β-nitrostyrenederivatives
exihibit antiproliferative properties by disrupting tubulinSarcoma 5
Control 2.5μMM N S 1μMM N S
5μM MNS 10μM MNS 10μM inactive analogue
Figure 3: MNS disrupts preformed metastatic 143B cell colonies in a dose-dependent manner. 143B cell colonies 4 hours after incubation in
the presence of increasing concentrations of MNS (1, 2.5, 5, and 10μM), 10μM of the inactive analogue, or 1% DMSO as a vehicle control.
This ﬁgure shows representative images from three independent experiments, each with three wells per group.
Control
10μM
10μM MNS inactive analogue
Figure 4: MNS disrupts preformed 143B colonies. Images of the metastatic 143B cell colonies incubated for 24 hours in presence of 10μM
MNS, 10μM of the inactive analogue, or 1% DMSO as a vehicle control. The membrane-impermanent ﬂuorescent stain 4 , 6-diamidino-2-
phenylindole (DAPI, 0.1μg/mL) was added 8 hours after incubation began. Fluorescent microscopy was used to obtain photomicrographs
(bottom panel). This ﬁgure shows representative images from three independent experiments, each with two to three wells per group.6 Sarcoma
Control
10μM 10μM
MNS
TE85
MNNG
SAOS-2
LM7
inactive analogue
Figure 5: MNS disrupts preformed colonies of the osteosarcoma cell lines. Representative photomicrographs for each cell line 24 hours
after incubation in the presence of 10μM MNS, 10μM of the inactive analogue, or 1% DMSO as a vehicle control. Each experiment was
performed in triplicate, each with three wells per group.
polymerization, which leads to conformational changes
in tubulin, and interrupts cellular mitosis [10, 40]. The
pro-apoptotic eﬀects of β-nitrostyrene compounds is due to
their inhibition of cellular protein phosphatases, including
serine/threonine phosphatases 1 and 2A (PP1 and PP2A)
and PTB1 [8, 42, 43]. For example, trans-β-nitrostyrene has
been shown to inhibit protein phosphatases PP2A and PTB1
leading to apoptosis in colon cancer cells [43]. Inhibition
of these protein phosphatases disrupts key cellular signal
transduction, and in the case of PP2A inhibition, Bcl-2
is consequently hyperphosphorylated, thus inhibiting Bcl-2
anti-apoptotic activity [43, 44]. In another study, McNamaraSarcoma 7
Control 100μM MNS
100μM
10μMM N S
143B
hOB
inactive analogue
SAECs
Figure 6: MNS also disrupts monolayers of osteosarcoma cells and osteoblasts but does not alter monolayers of small airway epithelial cells.
143B metastatic osteosarcoma cell line, normal human osteoblasts (hOB), and normal human small airway epithelial cells (SAEC) after
culture for 24 hours in the presence of 10μM MNS, 100μM MNS, 100μM of the inactive analogue, or 1% DMSO as a vehicle control. Figure
shows representative images from three independent experiments, each with three wells per group.
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Figure 7: Expression of syk (a) and src (b) mRNA levels in the osteosarcoma cell lines at mid-log phase. mRNA levels were normalized to
those of GAPDH. The asterisk denotes P<0.001 compared with the mRNA levels of the non-metastatic SAOS-2 cell line. Each reaction was
performed in triplicate.
et al. demonstrated nitrostyrene induction of chromatin
condensation, caspase activation, and membrane blebbing
leading to apoptosis in a Burkitt’s lymphoma derived cell
line [41]. Furthermore, Werner et al. reported rapid onset
of action as 50% decrease in colon cancer cell viability
was demonstrated after just 8 hours of exposure to the β-
nitrostyrene derivative [43].
beta-Nitrostyrene derivatives have also been shown to
be capable of telomerase inhibition [9]. One adaptive and
protective characteristic of various tumor cells is production8 Sarcoma
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Figure 8: Speciﬁc tyrosine kinase inhibitors of syk and src do not reduce motility or colony formation by the metastatic 143B cells (panel
(a) & (b)) or colony formation by the non-tumorigenic/non-metastatic TE85 cells (panel (c)). Motility and colony formation assays were
performed in the presence of tyrosine kinase inhibitors or 1% DMSO as a vehicle control. Bars represent the means ± standard error of the
mean of three individual experiments (scrape motility assays with four to six scrapes per group; colony formation assays with three wells per
group). Double asterisks denote P<0.001 compared with the vehicle control groups; single asterisk (panel (b)) denotes P = 0.012.
of telomerase which prevents telomere erosion during
repeated cell cycles [9, 45]. Telomerase eﬀectively prevents
cell senescence and prolongs the life of tumor cells [9, 45].
Cervical cancer cells treated with β-nitrostyrene compounds
are shown to possess telomere shortening and cellular
senescence in a dose-dependent manner [9].
The current literature lacks data involving safety proﬁles
for β-nitrostyrene derivatives regarding side eﬀects following
human administration. Compounds which possess target
speciﬁcity are ideal as they generally result in fewer side
eﬀects and better patient compliance. Since MNS and other
B-nitrosytrenes kill some but not all cancer cells [41], it is
likely that the eﬀects are speciﬁc for certain cell types. In this
study, the presence of MNS resulted in cell disruption and
death, both in the osteosarcoma cells and normal, human
osteoblasts.However,MNSapplicationdidnotdisruptorkill
small airway epithelial cells, but instead, the pulmonary cells
remained viable. These results outline the interest in MNS
as new chemotherapeutic option, potentially with a safety
proﬁle to permit nasal administration.
To the best of the author’s knowledge, this is the ﬁrst
report of utilizing the colony survival assays as outlined
within this paper. The concept of allowing tumorigenic
colony formation within a collagen matrix prior to the
addition of inhibitor may mimic treatment of patients with
pre-existing metastasis. The concept is important as all
osteosarcomapatientsarepresumedtohavemicrometastases
at time of diagnosis, approximately 20% of patients actually
present with clinically detectable metastases, and the leading
cause of death is pulmonary failure secondary to metastatic
disease [4]. Future goals include validating the proposed
clinical correlation of nonadherent colony survival assays
in an osteosarcoma animal model possessing metastatic
pulmonary nodes. The colony survival assay would likely
be helpful in the development of other chemotherapeutic
compounds.Sarcoma 9
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Figure 9: MNS does not inhibit activity of any of the 16 tyrosine kinases that were tested, including syk and src. In panel (a), the eﬀect of
10μM MNS was examined in the presence of the concentration of ATP that approximates the Km for the individual kinase. In panel (b), the
eﬀe c to f1 0o r1 0 0μM MNS was examined in the presence of 10μM ATP or the concentration of ATP that approximates the Km for src or
syk. All assays were performed in either triplicate or quadruplicate.
The in vitro nature of the motility, colony formation,
and colony survival experiments is a limitation of the study.
However, the in vitro motility and colony formation of the
human osteosarcoma cell lines correlates to their in vivo
tumorigenic and metastatic potential [14, 27, 29]. Future
studies are needed to determine whether the results of MNS
are replicated in vivo.
The decrease in motility, colony formation, and colony
survival of osteosarcoma cells following in vitro treatment
with MNS are encouraging. Future studies to identify the
target(s) responsible for the eﬀects of MNS on osteosarcoma
cells would oﬀer the possibility of developing chemothera-
peutics that are even more speciﬁc for the target(s).
5. Conclusion
MNS decreases the motility and colony formation of
osteosarcoma cells. MNS disrupts preformed osteosarcoma
cell colonies while producing little eﬀect on pulmonary
epithelial cells. Further investigations will unveil the full
potential of MNS as a new and useful chemotherapeutic
drug to be used clinically as part of a multi-drug strategy for
patients suﬀering from osteosarcoma.
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